We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Conygar Investment Company Plc (the) | LSE:CIC | London | Ordinary Share | GB0033698720 | ORD 5P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 77.50 | 75.00 | 80.00 | 77.50 | 77.50 | 77.50 | 1,200 | 08:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Real Estate Agents & Mgrs | 14.05M | -29.53M | -0.4952 | -1.57 | 46.22M |
From Apr 2022 to Apr 2024
TIDMCIC
RNS Number : 3524I
Conygar Investment Company PLC(The)
02 December 2022
[2nd December 2022]
THE CONYGAR INVESTMENT COMPANY PLC
Planning application for bioscience accommodation
at The Island Quarter, Nottingham
The Conygar Investment Company PLC ("Conygar") has submitted a detailed application for the next phase of The Island Quarter development in Nottingham. The application comprises a 23,123 sq.m. (249,000 sq.ft.) bioscience building, which includes both laboratory and office space.
Christopher Ware, Property Director of Conygar, commented:
"We are delighted to submit this application for the next phase of development. Nottingham is already home to a large number of exciting businesses in the bioscience space and this scheme will be an excellent addition to the mixed-use development we are creating at The Island Quarter".
Enquiries:
The Conygar Investment Company PLC
Christopher Ware: 020 7258 8670
Liberum Capital Limited (Nominated Adviser and Broker)
Richard Lindley: 020 3100 2185
Temple Bar Advisory (Public Relations)
Alex Child-Villiers: 07795 425580
William Barker: 07827 960151
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
MSCFSIFUFEESEEE
(END) Dow Jones Newswires
December 02, 2022 02:00 ET (07:00 GMT)
1 Year Conygar Investment Chart |
1 Month Conygar Investment Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
